These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 16548096

  • 1. Doxetaxel: new indication. Prostate cancer: a few more weeks.
    Prescrire Int; 2006 Feb; 15(81):6-7. PubMed ID: 16548096
    [Abstract] [Full Text] [Related]

  • 2. Mitoxantrone: new indication. More risky than beneficial in advanced prostate cancer.
    Prescrire Int; 2001 Aug; 10(54):110-2. PubMed ID: 11718179
    [Abstract] [Full Text] [Related]

  • 3. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
    Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED.
    N Engl J Med; 2004 Oct 07; 351(15):1513-20. PubMed ID: 15470214
    [Abstract] [Full Text] [Related]

  • 4. Trastuzumab: new indication. Metastatic breast cancer, in combination with docetaxel: promising, but more evaluation is needed.
    Prescrire Int; 2006 Feb 07; 15(81):3-5. PubMed ID: 16548094
    [Abstract] [Full Text] [Related]

  • 5. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
    de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, TROPIC Investigators.
    Lancet; 2010 Oct 02; 376(9747):1147-54. PubMed ID: 20888992
    [Abstract] [Full Text] [Related]

  • 6. Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer.
    Dagher R, Li N, Abraham S, Rahman A, Sridhara R, Pazdur R.
    Clin Cancer Res; 2004 Dec 15; 10(24):8147-51. PubMed ID: 15623588
    [Abstract] [Full Text] [Related]

  • 7. Future directions in the treatment of androgen-independent prostate cancer.
    Petrylak DP.
    Urology; 2005 Jun 15; 65(6 Suppl):8-12. PubMed ID: 15939077
    [Abstract] [Full Text] [Related]

  • 8. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
    Berry W, Eisenberger M.
    Oncologist; 2005 Jun 15; 10 Suppl 3():30-9. PubMed ID: 16368869
    [Abstract] [Full Text] [Related]

  • 9. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
    Van Poppel H.
    Can J Urol; 2005 Feb 15; 12 Suppl 1():81-5. PubMed ID: 15780173
    [Abstract] [Full Text] [Related]

  • 10. The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer.
    Berry WR.
    Urology; 2005 Jun 15; 65(6 Suppl):2-7. PubMed ID: 15939076
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic options in androgen-independent prostate cancer: building on docetaxel.
    Petrylak D.
    BJU Int; 2005 Dec 15; 96 Suppl 2():41-6. PubMed ID: 16359438
    [Abstract] [Full Text] [Related]

  • 12. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.
    Scher HI, Jia X, Chi K, de Wit R, Berry WR, Albers P, Henick B, Waterhouse D, Ruether DJ, Rosen PJ, Meluch AA, Nordquist LT, Venner PM, Heidenreich A, Chu L, Heller G.
    J Clin Oncol; 2011 Jun 01; 29(16):2191-8. PubMed ID: 21483004
    [Abstract] [Full Text] [Related]

  • 13. Which drug combination for hormone-refractory prostate cancer?
    Doggrell SA.
    Expert Opin Pharmacother; 2005 Apr 01; 6(4):667-70. PubMed ID: 15934892
    [Abstract] [Full Text] [Related]

  • 14. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.
    Hussain M, Petrylak D, Fisher E, Tangen C, Crawford D.
    Semin Oncol; 1999 Oct 01; 26(5 Suppl 17):55-60. PubMed ID: 10604271
    [Abstract] [Full Text] [Related]

  • 15. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
    Mackler NJ, Dunn RL, Hellerstedt B, Cooney KA, Fardig J, Olson K, Pienta KJ, Smith DC.
    Cancer; 2006 Jun 15; 106(12):2617-23. PubMed ID: 16691618
    [Abstract] [Full Text] [Related]

  • 16. Docetaxel (Taxotere) in hormone-refractory prostate cancer.
    Petrylak DP.
    Semin Oncol; 2000 Apr 15; 27(2 Suppl 3):24-9. PubMed ID: 10810935
    [Abstract] [Full Text] [Related]

  • 17. The case for early chemotherapy for the treatment of metastatic disease.
    Lucas A, Petrylak DP.
    J Urol; 2006 Dec 15; 176(6 Pt 2):S72-5. PubMed ID: 17084173
    [Abstract] [Full Text] [Related]

  • 18. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
    Saad F, Hotte S, North S, Eigl B, Chi K, Czaykowski P, Wood L, Pollak M, Berry S, Lattouf JB, Mukherjee SD, Gleave M, Winquist E, Canadian Uro-Oncology Group.
    Clin Cancer Res; 2011 Sep 01; 17(17):5765-73. PubMed ID: 21788353
    [Abstract] [Full Text] [Related]

  • 19. [Hormonoresistant metastatic prostate cancer: analysis of two phase III clinical studies].
    Ferrero JM.
    Bull Cancer; 2005 May 01; 92(5):425-7. PubMed ID: 15932803
    [Abstract] [Full Text] [Related]

  • 20. Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study.
    Font A, Murias A, Arroyo FR, Martin C, Areal J, Sanchez JJ, Santiago JA, Constenla M, Saladie JM, Rosell R.
    Ann Oncol; 2005 Mar 01; 16(3):419-24. PubMed ID: 15668260
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.